Urology Times· @UrologyTimes · X·· 22 小时前评分70
正文 · 原文
VOLGA at #ESMO2026: Perioperative durvalumab plus neoadjuvant enfortumab vedotin significantly improved EFS and OS in patients with MIBC ineligible for or refusing cisplatin. @tompowles1 https://www.urologytimes.com/view/volga-durvalumab-plus-enfortumab-vedotin-improves-efs-os-in-mibc
94 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA2按 Presidential Symposium I 对上
Perioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgVOLGA
https://esmocongress.esmo.org来源：Urology Times · x.com